Thomas Dubensky
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Thomas Dubensky
Thomas Dubensky is recorded as Board Member at Tempest Therapeutics, Inc. (TPST). Tempest Therapeutics, Inc. reported in an 8-K filed June 16, 2023 that Thomas Dubensky was appointed Class II director. The proxy statement of Tempest Therapeutics, Inc. reports total compensation of $1,100,586 for Thomas Dubensky in fiscal 2022, including a base salary of $489,541. Disclosed compensation is on record for 2 fiscal years.
“The Company’s stockholders elected the persons listed below as a Class II directors, to serve until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2021-07-07–present
-
Current
2021-01-01–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Tempest Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Julia C. Owens CEO, Chairman
- Louis J. Arcudi III CEO, CFO, Board Member
- Matt Angel CEO, Board Member
- Matt Angel, Ph.D. CEO, Board Member
- Stephen R. Brady CEO
- Mike Raab Chairman, Board Member
- Stephen Brady Chairman
- Constance Ames CFO
- Jennifer Minai-Azary CFO
- Justin Trojanowski CFO, Chief Accounting Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Tempest Therapeutics, Inc. (TPST) | President | $489,541 | $1,100,586 |
| 2021 | Tempest Therapeutics, Inc. (TPST) | President | $475,283 | $1,500,167 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.